Annette Matthies as CBO at Elicio Therapeutics
Elicio Therapeutics, a longstanding client of Occam Global's, has strengthened its leadership team with the appointment of Annette Matthies, PhD, as Chief Business Officer. Elicio Therapeutics is advancing its ground-breaking Amphiphile technology across immunotherapy and vaccine platforms to develop therapies for cancer and infectious disease.
Annette, trained as an immunologist and broadly experienced across therapeutic areas including oncology, will spearhead Elicio's business and corporate development initiatives with a particularly strong focus on partnership opportunities in 2021. Most recently, Annette served as VP of Corporate Development at eFFECTOR Therapeutics. Prior to that, she was an integral member of the corporate development teams of Receptos, acquired by Celgene for $7.2B, and Facet Biotech, acquired by Abbott Laboratories for $450M.
Previously, Occam placed Christopher Haqq MD/PhD as EVP, Head of R&D and Chief Medical Officer. More recently, Occam recruited Daphne Karydas to join Elicio's Board of Directors.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.